# Henry Schein (HSIC) — Earnings HSIC · NASDAQ · Stock Canonical page: https://www.lighthorse.io/tickers/hsic/earnings ## Most recent quarter | Metric | Value | | --- | --- | | Fiscal period | Q2 2026 | | Period end | Jun 27, 2026 | | EPS actual | $1.27 | | EPS estimate | $1.24 | | EPS surprise | +2.45% | | Revenue surprise | +2.49% | | Revenue | $3.5B | | Revenue estimate | $3.4B | | Reported | Aug 4, 2026 | | SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1000228/000100022826000045/hsic-20260627.htm) | | Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/5119d693-0da6-7674-8d25-2d33cd83bfd8.html) | Henry Schein reported Q2 2026 results on August 4, 2026. Earnings per share came in at $1.27, ahead of the $1.24 estimate by 2.45%. Revenue was $3.5 billion, above the $3.4 billion consensus by 2.49%. Compared with Q2 2025, EPS rose about 15% from $1.10 and revenue rose about 9% from $3.2 billion. The longer record shows modest, uneven growth. Annual EPS was $4.96 in 2022, dipped to $4.50 in 2023, then rose to $4.74 in 2024 and $4.97 in 2025. The weakest quarter in the table was Q4 2023, at $0.66 per share. The strongest was Q3 2025, at $1.38. Q2 2026 revenue of $3.5 billion was the highest in the table. The first half of 2026 adds up to $2.59 per share, about 15% more than the first half of 2025. Over the last 20 quarters, Henry Schein beat the EPS estimate 16 times. Its largest miss was Q2 2025, at 7.82%. Henry Schein reported Q3 between November 1 and November 13 in each of the past five years. That points to early November 2026 for the next report. It will show whether the first-half gains carry into the third quarter. ## Earnings history | Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual | | --- | --- | --- | --- | --- | --- | --- | | Q2 2026 | Aug 4, 2026 | $1.24 | $1.27 | 2.45% | $3.4B | $3.5B | | Q1 2026 | May 5, 2026 | $1.22 | $1.32 | 8.38% | $3.3B | $3.4B | | Q4 2025 | Feb 24, 2026 | $1.30 | $1.34 | 3.01% | $3.3B | $3.4B | | Q3 2025 | Nov 4, 2025 | $1.28 | $1.38 | 8.06% | $3.3B | $3.3B | | Q2 2025 | Aug 5, 2025 | $1.19 | $1.10 | -7.82% | $3.2B | $3.2B | | Q1 2025 | May 5, 2025 | $1.11 | $1.15 | 3.37% | $3.2B | $3.2B | | Q4 2024 | Feb 25, 2025 | $1.20 | $1.19 | -1.18% | $3.3B | $3.2B | | Q3 2024 | Nov 5, 2024 | $1.17 | $1.22 | 4.29% | $3.2B | $3.2B | | Q2 2024 | Aug 6, 2024 | $1.22 | $1.23 | 0.93% | $3.3B | $3.1B | | Q1 2024 | May 7, 2024 | $1.02 | $1.10 | 8.23% | $3.2B | $3.2B | | Q4 2023 | Feb 27, 2024 | $0.70 | $0.66 | -5.20% | $3.0B | $3.0B | | Q3 2023 | Nov 13, 2023 | $1.32 | $1.32 | 0.20% | $3.2B | $3.2B | | Q2 2023 | Aug 7, 2023 | $1.28 | $1.31 | 2.64% | $3.1B | $3.1B | | Q1 2023 | May 9, 2023 | $1.23 | $1.21 | -1.79% | $3.1B | $3.1B | | Q4 2022 | Feb 16, 2023 | $1.22 | $1.35 | 10.51% | $3.4B | $3.4B | | Q3 2022 | Nov 1, 2022 | $1.14 | $1.15 | 0.75% | $3.2B | $3.1B | | Q2 2022 | Aug 2, 2022 | $1.13 | $1.16 | 2.36% | $3.1B | $3.0B | | Q1 2022 | May 3, 2022 | $1.19 | $1.30 | 9.66% | $3.1B | $3.2B | | Q4 2021 | Feb 15, 2022 | $0.92 | $1.07 | 15.85% | $3.2B | $3.3B | | Q3 2021 | Nov 2, 2021 | $0.95 | $1.10 | 16.11% | $2.9B | $3.2B | ## Frequently Asked Questions ### When did Henry Schein (HSIC) last report earnings? Henry Schein last reported on Aug 4, 2026, covering fiscal Q2 2026. ### Did HSIC beat earnings estimates? Yes. Henry Schein reported EPS of $1.27 for Q2 2026 against a $1.24 estimate — a 2.45% beat. ### How much revenue did HSIC report last quarter? Henry Schein reported $3.5B in revenue for Q2 2026, against a consensus estimate of $3.4B. ## Similar Stocks - [AMN](https://www.lighthorse.io/tickers/amn) — AMN Healthcare Services Inc - [WST](https://www.lighthorse.io/tickers/wst) — West Pharmaceutical Services, Inc. Common Stock - [NVST](https://www.lighthorse.io/tickers/nvst) — Envista Holdings Corporation Common Stock - [IDXX](https://www.lighthorse.io/tickers/idxx) — IDEXX Laboratories, Inc. - Common Stock - [BIO](https://www.lighthorse.io/tickers/bio) — Bio-Rad Laboratories, Inc. Class A Common Stock - [MMSI](https://www.lighthorse.io/tickers/mmsi) — Merit Medical Systems, Inc. - Common Stock - [COO](https://www.lighthorse.io/tickers/coo) — The Cooper Companies, Inc. - Common Stock - [BRBR](https://www.lighthorse.io/tickers/brbr) — BellRing Brands, Inc. Common Stock - [PODD](https://www.lighthorse.io/tickers/podd) — Insulet Corporation - Common Stock - [VEEV](https://www.lighthorse.io/tickers/veev) — Veeva Systems Inc. Class A Common Stock --- Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance. This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness. Data provided by [AInvest](https://www.ainvest.com).